Jyong Biotech Ltd. MENS
2.03
(0.12)
(5.58%)
as of 25 Sep
- Market cap
- $162.6M
- P/E
- —
Follow MENS
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
Current Ratio |
0.13 | 0.02 | 0.45 |
Net Debt/EBITDA |
(5.52) | (9.22) | (6.89) |
Debt/Assets |
199.95% | 282.12% | 88.76% |
Debt/Equity |
(0.48) | (0.49) | (0.74) |
Asset Turnover |
— | 0.00 | 0.00 |
Operating CF/Net income |
0.59 | 1.20 | 0.65 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 |
| 0.00% | 8.55% | 15.21% | |
| 0.00% | (41.32%) | (34.42%) | |
ROIC |
0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
48.71% | 34.03% | 28.87% |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.04) | (0.05) | (0.04) |
Cash per Share |
0.02 | 0.00 | 0.02 |
Shareholders Equity per Share |
(0.48) | (0.51) | (0.34) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(0.48) | (0.51) | (0.34) |
Free Cash Flow |
(2.60) | (3.62) | (3.04) |
Working Capital |
(12.42) | (11.92) | (19.27) |
Net Current Asset Value |
(40.48) | (42.68) | (30.14) |
| Other line items | |||
Quick Ratio |
0.12 | 0.01 | 0.03 |
Depreciation/Fixed assets |
0.04 | 0.04 | 0.03 |
Cash ROIC |
37.80% | 36.15% | 115.95% |
Accounts Payable Turnover |
— | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.04) | (0.05) | (0.04) |
Capex per Share |
0.00 | 0.00 | 0.00 |
Average Payables |
— | 0.00 | 0.00 |
Average Assets |
— | 7.31 | 13.57 |
Average Common Equity |
— | (35.30) | (30.71) |
Net Profit Margin |
0.00% | 0.00% | 0.00% |
Columns are period end dates